Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA on Nasdaq, is a clinical-stage biopharmaceutical company focused on developing non-opioid pain therapies, including its lead asset SP-102, a viscous gel formulation of dexamethasone designed for epidural use. The company became publicly listed through its business combination with Denali Capital Acquisition Corp., a blank-check company that completed its IPO in 2021 and was sponsored by Denali Capital Group. Semnur filed a Form 10-Q with the SEC on November 19, 2024, covering its most recent quarterly period, reflecting its ongoing reporting obligations as a post-merger public company in the healthcare and life sciences sector. Visit SpacDesk and create a free account for complete financial filings, deal timelines, and sponsor analytics on DECA and hundreds of other SPAC transactions.